Welcome to our dedicated page for Surrozen Common news (Ticker: $SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen Common stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Surrozen Common's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Surrozen Common's position in the market.
Rhea-AI Summary
Surrozen, Inc. (SRZN) announces promising results in treating idiopathic pulmonary fibrosis with their Wnt mimetic technologies. The preclinical model showed a decrease in pulmonary inflammation and fibrosis, improved lung function, and expansion of alveolar organoid cultures. The publication in Respiratory Research highlights the potential of Wnt mimetic agonists in repairing tissue after severe lung damage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.41%
Tags
-
Rhea-AI Summary
Surrozen, Inc. secures $17.5 million upfront proceeds, with potential for an additional $175 million, through securities purchase agreements. The funds will expand Phase 1b trial in severe alcohol-associated hepatitis and prolong cash runway. Phase Ib data from the expanded study is anticipated in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.71%
Tags
-
Rhea-AI Summary
Surrozen, Inc. announces positive Phase 1a trial results for SZN-043, showing safety, target engagement, and liver function improvement. The company plans to initiate a Phase 1b trial in severe alcohol-associated hepatitis and present data at a medical meeting in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.71%
Tags
Rhea-AI Summary
Surrozen, Inc. announced the strategic prioritization of clinical programs, focusing on the development of SZN-043 for Alcohol-Associated Hepatitis. The company completed enrollment for the Phase 1a clinical trial in chronic liver disease patients and healthy volunteers. They expect to announce Phase 1a safety and pharmacodynamic data in Q1 2024 and initiate enrollment in the Phase 1b clinical trial in patients with alcohol-associated hepatitis in 2024. Surrozen also anticipates proof-of-concept data may be available in the second half of 2024. The company has discontinued clinical development of SZN-1326 in inflammatory bowel disease due to challenges in identifying a safe and effective dose and other strategic considerations. Surrozen has $43.4 million in cash, cash equivalents, and marketable securities as of September 30, 2023, resulting in a cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.53%
Tags
-
Rhea-AI Summary
SRZN: Surrozen Announces Phase 1a Clinical Trial Updates and Financial Results for Q3 2023, Strengthened Portfolio and Cash Position
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.19%
Tags
-
Rhea-AI Summary
Surrozen, Inc. (SRZN) provided Q2 2023 financial results and updates on Phase 1a clinical trials for SZN-043 and SZN-1326. The company aims to extend cash runway into 2025 through corporate prioritization efforts. SZN-043's Phase 1b trial for alcoholic hepatitis and SZN-1326's Phase 1b trial for ulcerative colitis are anticipated to initiate in 2024, with proof of concept data expected in the second half of 2024. Surrozen's partnership with Boehringer Ingelheim is set to potentially trigger a $10.0 million milestone payment upon nomination of the lead Fzd-4 targeted Wnt agonist development candidate in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.21%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.46%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.56%
Tags
Surrozen, Inc. Common
Nasdaq:SRZN
SRZN Rankings
SRZN Stock Data
31.86M
1.67M
5.73%
48.75%
0.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
SOUTH SAN FRANCISCO
About SRZN
surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the wnt signaling pathway. surrozen is founded by four leading edge scientists from stanford university: k. christopher garcia, ph.d.; roel nusse, ph.d.; calvin kuo, m.d., ph.d.; and claudia janda, ph.d. each has conducted extensive research on wnt signaling, with findings that together shape surrozen’s technology and approach to therapeutic development. the company is backed by the column group, a leading biotechnology venture capital firm. we are currently seeking highly creative scientists to join our founding team, and invite you to explore career opportunities on our website. if you don’t find a perfect job match, but think surrozen may be the right place for you, please submit your resume to careers@surrozen.com.